Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A patient-clinician call for global harmonization of access to second-line medical therapies for acromegaly in the era of personalized medicine.

Created on 19 Nov 2026

Authors

Manel Puig-Domingo, Rosalind Way, Raquel Ciriza, Andrea Giutina

Published in

Pituitary. Volume 29. Issue 6. Nov 18, 2026. Epub Nov 18, 2026.

Abstract

In the European Union (EU) and the United Kingdom (UK), the Summaries of Product Characteristics (SmPC) of pegvisomant (PEGV) and pasireotide LAR (PAS-LAR) require inadequate control on prior somatostatin analogue treatment (or intolerance for PEGV), unlike US labelling. These regulatory differences should be distinguished from inequalities in actual treatment access.
To assess whether these regulatory differences remain justified in light of predictive evidence, current consensus recommendations and patient needs.
Narrative review of EU and UK regulatory documents, pivotal trials, consensus statements and biomarker-guided trials, integrated with the patient perspective.
Validated clinical, imaging, functional and pathological predictors identify patients with a low probability of fgSRL response. Updated consensus guidelines increasingly recognize the importance to use biomarker-guided treatment rather than trial-error strategy choice and recommended as the best care modality allowing aalthough response predictors for first-generation somatostatin receptor ligands (fgSRLs) differ in accuracy and clinical readiness and for PAS-LAR they still remain to be confirmed .
Patients and clinicians propose reconsidering labels to enable earlier individualized treatment in selected patients, subject to drug-specific evidence and safety monitoring. This proposal extends beyond current recommendations for PAS-LAR; label harmonization would allow equitable access.

PMID:
43050034
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement